Loading...

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

BACKGROUND: Targeted therapies significantly improve clinical outcomes among patients with metastatic renal cell carcinoma (mRCC). Several new agents have been approved for first- and second-line use. However, there is a lack of compelling evidence comparing sequencing strategies, and available comp...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pathol Oncol Res
Main Authors: Géczi, Lajos, Bodoky, György, Rokszin, György, Fábián, Ibolya, Torday, László
Format: Artigo
Sprog:Inglês
Udgivet: Springer Netherlands 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471136/
https://ncbi.nlm.nih.gov/pubmed/32291570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12253-020-00809-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!